IJRAP International Journal of Research in Ayurveda and Pharmacy 2277-4343 Moksha Publishing House DOI: 10.7897/2277-4343.1006116 TAXOL AS AN ANTICANCER AGENT: A REVIEW Sachin Aglawe * Amol Gayke Pratik Kadam Shubham Kanawade Yogesh Garud 11 -0001 15 17 The development of Taxol__ampersandsignnbsp;(paclitaxel) as an anticancer drug is reviewed. Paclitaxel (formerly called taxol), an important anticancer drug, inhibits cell replication by binding to and stabilizing microtubule polymers. As drug-receptor interactions are governed by the three-dimensional stereochemistry of both participants. Paclitaxel (Taxol) is a chemotherapy drug widely used to treat different types of solid tumours (e.g. ovarian, breast, and pancreatic). Taxol acts by hyper-stabilizing microtubules, inhibiting mitosis and eventually causing cell apoptosis. Taxol belongs to a class of chemotherapy drugs called plant alkaloids. Plant alkaloids are made from plants. From long time paclitaxel is used to induce mitotic arrest, which is responsible for cell death in a subset of the arrested population. Now it is demonstrated that intra-tumoral concentration of paclitaxel are low to produce mitotic arrest and which result in multi polar division instead. It may possible that this insight can be used to develop a biomarker to identify the 50% patients may set benefit from paclitaxel therapy. This review includes common and less common side effects for individuals taking Taxol.__ampersandsignnbsp; Side effects that is very rare, occurring in less than 10% of patients. Here I discuss the history of paclitaxel and our recently evolved understanding of its mechanism of action. Taxol Anticancer agent chemotherapy.